High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells

Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells

(2010) M. Bleakley et al.   BLOOD

Efficacious Immune Therapy in Chronic Myelogenous Leukemia (CML) Recognizes Antigens That Are Expressed on CML Progenitor Cells

(2010) M. A. Biernacki et al.   CANCER RESEARCH

Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia

(2010) Tim Luetkens et al.   LEUKEMIA RESEARCH

The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells

(2009) V. G. Oehler et al.   BLOOD

Adoptive cell therapy for the treatment of patients with metastatic melanoma

(2009) Steven A Rosenberg et al.   CURRENT OPINION IN IMMUNOLOGY

Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia

(2008) K. Rezvani et al.   BLOOD

Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia

(2008) C. Quintarelli et al.   BLOOD

Expression of Angiotensin-converting Enzyme Changes Major Histocompatibility Complex Class I Peptide Presentation by Modifying C Termini of Peptide Precursors

(2008) Xiao Z. Shen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Chronic Myeloid Leukemia Stem Cells

(2008) Edward Kavalerchik et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Outcome of Complete Cytogenetic Responders After Imatinib 400 mg in Late Chronic Phase, Philadelphia-Positive Chronic Myeloid Leukemia: The GIMEMA Working Party on CML

(2007) Francesca Palandri et al.   JOURNAL OF CLINICAL ONCOLOGY